[
  {
    "id": "assay-tisa-cyto-nalm6-001",
    "text_summary": "Tisagenlecleucel (CTL019) demonstrated potent cytotoxicity against CD19+ Nalm-6 B-ALL cells in vitro. At E:T ratio of 10:1, specific lysis reached 92% after 24h co-culture, with near-complete elimination of target cells by 48h. Untransduced T-cells showed <5% killing. Data from preclinical characterization supporting ELIANA trial (Maude et al., NEJM 2018).",
    "assay_type": "cytotoxicity",
    "construct_id": "fda-tisagenlecleucel",
    "target_antigen": "CD19",
    "cell_line": "Nalm-6",
    "effector_ratio": "10:1",
    "key_metric": "% specific lysis",
    "metric_value": 92.0,
    "outcome": "success",
    "notes": "PMID:29385376. 4-1BB costimulatory domain. Lentiviral vector."
  },
  {
    "id": "assay-tisa-cyto-raji-002",
    "text_summary": "Tisagenlecleucel showed effective killing of CD19+ Raji Burkitt lymphoma cells in chromium release assay. At 10:1 E:T ratio, 78% specific lysis was observed at 4h. Dose-dependent killing confirmed across E:T ratios 1:1 to 20:1 with EC50 at approximately 3:1.",
    "assay_type": "cytotoxicity",
    "construct_id": "fda-tisagenlecleucel",
    "target_antigen": "CD19",
    "cell_line": "Raji",
    "effector_ratio": "10:1",
    "key_metric": "% specific lysis",
    "metric_value": 78.0,
    "outcome": "success",
    "notes": "Burkitt lymphoma model. 4h chromium release assay."
  },
  {
    "id": "assay-tisa-cytokine-ifng-003",
    "text_summary": "Tisagenlecleucel CAR-T cells produced robust IFN-gamma secretion upon co-culture with CD19+ Nalm-6 cells. Mean IFN-gamma concentration of 12,450 pg/mL at 24h (E:T 1:1), compared to <50 pg/mL from untransduced controls. Cytokine production correlated with target cell killing efficiency.",
    "assay_type": "cytokine",
    "construct_id": "fda-tisagenlecleucel",
    "target_antigen": "CD19",
    "cell_line": "Nalm-6",
    "effector_ratio": "1:1",
    "key_metric": "IFN-gamma (pg/mL)",
    "metric_value": 12450.0,
    "outcome": "success",
    "notes": "ELISA measurement. 24h co-culture supernatant."
  },
  {
    "id": "assay-tisa-persist-004",
    "text_summary": "In the ELIANA trial, tisagenlecleucel demonstrated exceptional long-term persistence in pediatric B-ALL patients. CAR-T cells were detectable by qPCR in 68% of responders at 6 months post-infusion, with functional B-cell aplasia persisting as a surrogate marker. Median transgene persistence was 168 days. 4-1BB costimulation associated with superior T-cell longevity compared to CD28-based CARs (Maude et al., NEJM 2018).",
    "assay_type": "persistence",
    "construct_id": "fda-tisagenlecleucel",
    "target_antigen": "CD19",
    "cell_line": "",
    "effector_ratio": "",
    "key_metric": "% detectable at 6mo",
    "metric_value": 68.0,
    "outcome": "success",
    "notes": "PMID:29385376. ELIANA trial. n=75 patients. qPCR detection in blood."
  },
  {
    "id": "assay-tisa-invivo-nsg-005",
    "text_summary": "In NSG mouse xenograft model bearing Nalm-6 B-ALL tumors, tisagenlecleucel achieved complete tumor clearance in 9/10 mice by day 28. Bioluminescence imaging confirmed >3-log reduction in tumor burden by day 14. Dose: 1e7 CAR-T cells IV. Survival extended beyond 60 days vs median 25 days for controls.",
    "assay_type": "in_vivo",
    "construct_id": "fda-tisagenlecleucel",
    "target_antigen": "CD19",
    "cell_line": "Nalm-6 xenograft",
    "effector_ratio": "",
    "key_metric": "complete response rate",
    "metric_value": 90.0,
    "outcome": "success",
    "notes": "NSG mouse model. 1e7 CAR-T IV dose. BLI imaging."
  },
  {
    "id": "assay-axi-cyto-raji-006",
    "text_summary": "Axicabtagene ciloleucel (KTE-C19) demonstrated rapid and potent cytotoxicity against CD19+ Raji lymphoma cells. At 5:1 E:T ratio, >95% killing at 16h. CD28 costimulatory domain drives faster effector function compared to 4-1BB-based CARs. Supported ZUMA-1 trial design (Neelapu et al., NEJM 2017).",
    "assay_type": "cytotoxicity",
    "construct_id": "fda-axicabtagene-ciloleucel",
    "target_antigen": "CD19",
    "cell_line": "Raji",
    "effector_ratio": "5:1",
    "key_metric": "% specific lysis",
    "metric_value": 95.0,
    "outcome": "success",
    "notes": "PMID:29226797. CD28 costimulatory domain. Retroviral vector (gamma)."
  },
  {
    "id": "assay-axi-cytokine-multi-007",
    "text_summary": "Axicabtagene ciloleucel exhibited a rapid and intense cytokine release profile upon CD19+ target engagement. IFN-gamma peaked at 18,200 pg/mL (24h), IL-2 at 3,400 pg/mL, and TNF-alpha at 1,850 pg/mL. CD28-costimulated CAR-T cells showed 2-3x higher peak cytokine levels compared to 4-1BB constructs, correlating with higher CRS rates observed clinically in ZUMA-1.",
    "assay_type": "cytokine",
    "construct_id": "fda-axicabtagene-ciloleucel",
    "target_antigen": "CD19",
    "cell_line": "Raji",
    "effector_ratio": "1:1",
    "key_metric": "IFN-gamma (pg/mL)",
    "metric_value": 18200.0,
    "outcome": "success",
    "notes": "PMID:29226797. Multiplex cytokine analysis. Higher CRS risk with CD28."
  },
  {
    "id": "assay-axi-persist-008",
    "text_summary": "In ZUMA-1, axicabtagene ciloleucel CAR-T cell levels peaked at day 7-14 post-infusion (median 43 cells/uL) but declined rapidly. Only 34% of patients had detectable CAR-T cells at 6 months by flow cytometry. CD28 costimulation associated with rapid expansion but shorter persistence compared to 4-1BB CARs (Neelapu et al., NEJM 2017).",
    "assay_type": "persistence",
    "construct_id": "fda-axicabtagene-ciloleucel",
    "target_antigen": "CD19",
    "cell_line": "",
    "effector_ratio": "",
    "key_metric": "% detectable at 6mo",
    "metric_value": 34.0,
    "outcome": "partial",
    "notes": "PMID:29226797. ZUMA-1 trial. n=101 patients. Flow cytometry."
  },
  {
    "id": "assay-axi-exhaust-009",
    "text_summary": "Axicabtagene ciloleucel CAR-T cells from ZUMA-1 patients showed progressive exhaustion marker upregulation. PD-1 expression increased from 25% pre-infusion to 72% at day 7 peak expansion. LAG-3 co-expression on 41% of CAR-T cells at peak. TIM-3+PD-1+ double-positive T-cells correlated with reduced long-term persistence and eventual loss of response in relapsing patients.",
    "assay_type": "exhaustion",
    "construct_id": "fda-axicabtagene-ciloleucel",
    "target_antigen": "CD19",
    "cell_line": "",
    "effector_ratio": "",
    "key_metric": "% PD-1+ at peak",
    "metric_value": 72.0,
    "outcome": "partial",
    "notes": "ZUMA-1 correlative analysis. CD28 CARs show faster exhaustion kinetics."
  },
  {
    "id": "assay-axi-invivo-nsg-010",
    "text_summary": "In NSG mice bearing systemic Raji DLBCL tumors, axicabtagene ciloleucel at 5e6 CAR-T cells IV eradicated tumors in 8/10 mice by day 21. Rapid tumor clearance within first 7 days reflecting CD28-driven fast kinetics. However, late relapses observed in 2/8 initial responders by day 60, potentially due to CAR-T exhaustion.",
    "assay_type": "in_vivo",
    "construct_id": "fda-axicabtagene-ciloleucel",
    "target_antigen": "CD19",
    "cell_line": "Raji xenograft",
    "effector_ratio": "",
    "key_metric": "complete response rate",
    "metric_value": 80.0,
    "outcome": "success",
    "notes": "NSG mouse systemic tumor model. Late relapses in 25% of responders."
  },
  {
    "id": "assay-brex-cyto-jeko1-011",
    "text_summary": "Brexucabtagene autoleucel (KTE-X19) showed high cytotoxicity against CD19+ JeKo-1 mantle cell lymphoma cells. At 5:1 E:T ratio, 88% killing observed at 24h. Importantly, product manufactured with enriched T-cell process (T-cell selection prior to activation) showed more consistent killing across patient lots compared to standard leukapheresis-based manufacturing.",
    "assay_type": "cytotoxicity",
    "construct_id": "fda-brexucabtagene-autoleucel",
    "target_antigen": "CD19",
    "cell_line": "JeKo-1",
    "effector_ratio": "5:1",
    "key_metric": "% specific lysis",
    "metric_value": 88.0,
    "outcome": "success",
    "notes": "ZUMA-2. MCL model. Enriched T-cell manufacturing process."
  },
  {
    "id": "assay-brex-invivo-012",
    "text_summary": "In ZUMA-2 clinical trial for relapsed/refractory mantle cell lymphoma, brexucabtagene autoleucel achieved 93% ORR (67% CR) in 68 evaluable patients. Median time to response was 1.0 month. CAR-T expansion peaked at day 8 with median 122 cells/uL. Durable responses observed with 57% remaining in response at 12 months (Wang et al., NEJM 2020).",
    "assay_type": "in_vivo",
    "construct_id": "fda-brexucabtagene-autoleucel",
    "target_antigen": "CD19",
    "cell_line": "",
    "effector_ratio": "",
    "key_metric": "% ORR",
    "metric_value": 93.0,
    "outcome": "success",
    "notes": "PMID:32023374. ZUMA-2 trial. n=68 MCL patients. CD28 costimulation."
  },
  {
    "id": "assay-liso-cyto-nalm6-013",
    "text_summary": "Lisocabtagene maraleucel (liso-cel) demonstrated potent and dose-dependent cytotoxicity against Nalm-6 B-ALL cells. At 10:1 E:T ratio, 94% killing at 24h. Unique feature: defined composition product with fixed CD4:CD8 ratio (1:1), resulting in more reproducible killing across patient lots compared to unselected products.",
    "assay_type": "cytotoxicity",
    "construct_id": "fda-lisocabtagene-maraleucel",
    "target_antigen": "CD19",
    "cell_line": "Nalm-6",
    "effector_ratio": "10:1",
    "key_metric": "% specific lysis",
    "metric_value": 94.0,
    "outcome": "success",
    "notes": "TRANSFORM trial. Fixed CD4:CD8 1:1 ratio product. 4-1BB costim."
  },
  {
    "id": "assay-liso-cytokine-014",
    "text_summary": "Lisocabtagene maraleucel showed a favorable cytokine release profile compared to CD28-based CARs. IFN-gamma peaked at 8,900 pg/mL (24h co-culture with Raji cells), approximately 50% lower than axicabtagene. IL-6 levels were correspondingly lower, correlating with the reduced CRS rates observed in the TRANSCEND NHL 001 and TRANSFORM trials.",
    "assay_type": "cytokine",
    "construct_id": "fda-lisocabtagene-maraleucel",
    "target_antigen": "CD19",
    "cell_line": "Raji",
    "effector_ratio": "1:1",
    "key_metric": "IFN-gamma (pg/mL)",
    "metric_value": 8900.0,
    "outcome": "success",
    "notes": "4-1BB costim associated with lower cytokine peaks and reduced CRS risk."
  },
  {
    "id": "assay-liso-persist-015",
    "text_summary": "Lisocabtagene maraleucel demonstrated favorable persistence kinetics in TRANSCEND NHL 001. CAR-T cells detectable by qPCR in 73% of patients at 6 months and 51% at 12 months. The 4-1BB costimulatory domain and defined CD4:CD8 composition contributed to sustained central memory T-cell phenotype. B-cell recovery observed in some patients with declining CAR-T levels.",
    "assay_type": "persistence",
    "construct_id": "fda-lisocabtagene-maraleucel",
    "target_antigen": "CD19",
    "cell_line": "",
    "effector_ratio": "",
    "key_metric": "% detectable at 12mo",
    "metric_value": 51.0,
    "outcome": "success",
    "notes": "TRANSCEND NHL 001. 4-1BB + defined CD4:CD8 ratio enhances persistence."
  },
  {
    "id": "assay-ide-cyto-rpmi8226-016",
    "text_summary": "Idecabtagene vicleucel (ide-cel, bb2121) demonstrated BCMA-dependent cytotoxicity against RPMI-8226 multiple myeloma cells expressing high BCMA. At 5:1 E:T ratio, 85% killing at 24h. Minimal killing (<10%) of BCMA-negative K562 control cells confirmed target specificity. Killing efficiency correlated with surface BCMA density on target cells.",
    "assay_type": "cytotoxicity",
    "construct_id": "fda-idecabtagene-vicleucel",
    "target_antigen": "BCMA",
    "cell_line": "RPMI-8226",
    "effector_ratio": "5:1",
    "key_metric": "% specific lysis",
    "metric_value": 85.0,
    "outcome": "success",
    "notes": "PMID:33626253. KarMMa trial preclinical. 4-1BB costim. BCMA-dependent."
  },
  {
    "id": "assay-ide-cyto-mm1s-017",
    "text_summary": "Idecabtagene vicleucel showed strong killing of MM.1S multiple myeloma cells (moderate BCMA expression) with 72% lysis at 5:1 E:T ratio. Against U266 cells (low BCMA expression), killing dropped to 45%, demonstrating the dependence on antigen density. This BCMA density-dependent killing has implications for resistance via BCMA downregulation.",
    "assay_type": "cytotoxicity",
    "construct_id": "fda-idecabtagene-vicleucel",
    "target_antigen": "BCMA",
    "cell_line": "MM.1S",
    "effector_ratio": "5:1",
    "key_metric": "% specific lysis",
    "metric_value": 72.0,
    "outcome": "success",
    "notes": "Antigen density-dependent killing. Low-BCMA U266: only 45% killing."
  },
  {
    "id": "assay-ide-invivo-karmma-018",
    "text_summary": "In the KarMMa trial, idecabtagene vicleucel achieved 73% ORR (33% CR/sCR) across all dose levels (150-450 x10e6 cells) in relapsed/refractory multiple myeloma patients with >= 3 prior lines of therapy. At the highest dose (450 x10e6), ORR was 82% with 39% CR. Median duration of response was 10.7 months (Munshi et al., NEJM 2021).",
    "assay_type": "in_vivo",
    "construct_id": "fda-idecabtagene-vicleucel",
    "target_antigen": "BCMA",
    "cell_line": "",
    "effector_ratio": "",
    "key_metric": "% ORR",
    "metric_value": 73.0,
    "outcome": "success",
    "notes": "PMID:33626253. KarMMa trial. n=128. Dose-response relationship confirmed."
  },
  {
    "id": "assay-ide-persist-019",
    "text_summary": "Idecabtagene vicleucel CAR-T cells showed moderate persistence in KarMMa. Detectable in 45% of patients at 6 months by qPCR. Median peak expansion at day 11 (26 cells/uL). Patients achieving CR had significantly higher peak CAR-T expansion (median 54 vs 12 cells/uL, p<0.001). Loss of detectable CAR-T cells often preceded clinical relapse.",
    "assay_type": "persistence",
    "construct_id": "fda-idecabtagene-vicleucel",
    "target_antigen": "BCMA",
    "cell_line": "",
    "effector_ratio": "",
    "key_metric": "% detectable at 6mo",
    "metric_value": 45.0,
    "outcome": "partial",
    "notes": "KarMMa correlative. Higher expansion = better outcomes."
  },
  {
    "id": "assay-cilta-cyto-rpmi8226-020",
    "text_summary": "Ciltacabtagene autoleucel (cilta-cel) with its dual BCMA-binding VHH domain showed exceptional cytotoxicity against RPMI-8226 myeloma cells. At 1:1 E:T ratio, 89% killing at 24h — substantially higher than single-epitope BCMA CARs at the same ratio. The bivalent VHH design provides higher avidity binding that may overcome BCMA density heterogeneity.",
    "assay_type": "cytotoxicity",
    "construct_id": "fda-ciltacabtagene-autoleucel",
    "target_antigen": "BCMA",
    "cell_line": "RPMI-8226",
    "effector_ratio": "1:1",
    "key_metric": "% specific lysis",
    "metric_value": 89.0,
    "outcome": "success",
    "notes": "PMID:34534922. CARTITUDE-1. Dual VHH nanobody. Superior to single-chain."
  },
  {
    "id": "assay-cilta-cyto-lowbcma-021",
    "text_summary": "Ciltacabtagene autoleucel maintained high killing efficiency even against cells with low BCMA surface density. Against BCMA-low NCI-H929 cells, 76% lysis at 1:1 E:T ratio, compared to only 35% for single-epitope BCMA CARs. This enhanced activity against low-BCMA targets may explain the deeper and more durable responses observed in CARTITUDE-1 vs KarMMa.",
    "assay_type": "cytotoxicity",
    "construct_id": "fda-ciltacabtagene-autoleucel",
    "target_antigen": "BCMA",
    "cell_line": "NCI-H929",
    "effector_ratio": "1:1",
    "key_metric": "% specific lysis",
    "metric_value": 76.0,
    "outcome": "success",
    "notes": "Low-BCMA model. Dual VHH overcomes antigen density limitation."
  },
  {
    "id": "assay-cilta-invivo-cartitude-022",
    "text_summary": "In CARTITUDE-1, ciltacabtagene autoleucel achieved 98% ORR (83% sCR) in 97 heavily pretreated multiple myeloma patients (median 6 prior lines). Median time to first response: 1.0 month. At 27-month follow-up, median PFS was 27.7 months. Deepening responses over time with MRD-negativity in 92% of evaluable CR patients (Berdeja et al., Lancet 2021).",
    "assay_type": "in_vivo",
    "construct_id": "fda-ciltacabtagene-autoleucel",
    "target_antigen": "BCMA",
    "cell_line": "",
    "effector_ratio": "",
    "key_metric": "% sCR",
    "metric_value": 83.0,
    "outcome": "success",
    "notes": "PMID:34534922. CARTITUDE-1. n=97. Best-in-class BCMA CAR-T results."
  },
  {
    "id": "assay-cilta-persist-023",
    "text_summary": "Ciltacabtagene autoleucel showed exceptional persistence in CARTITUDE-1. CAR-T cells detectable in 75% of patients at 12 months post-infusion by qPCR. Median peak expansion at day 13 (850 copies/ug DNA). The dual-VHH design combined with 4-1BB costimulation may contribute to sustained CAR-T persistence and deepening MRD-negative responses over time.",
    "assay_type": "persistence",
    "construct_id": "fda-ciltacabtagene-autoleucel",
    "target_antigen": "BCMA",
    "cell_line": "",
    "effector_ratio": "",
    "key_metric": "% detectable at 12mo",
    "metric_value": 75.0,
    "outcome": "success",
    "notes": "CARTITUDE-1. Best persistence among BCMA CARs. Dual VHH + 4-1BB."
  },
  {
    "id": "assay-cd19-resist-loss-024",
    "text_summary": "Analysis of CD19 CAR-T relapse mechanisms across 145 patients from ELIANA and ZUMA-1 trials revealed antigen loss as the dominant resistance mechanism. CD19-negative relapse occurred in 28% of patients who initially responded then relapsed. Mechanisms include: CD19 exon 2 frameshift mutations (39%), alternative splicing skipping exon 2 (29%), and lineage switch to myeloid phenotype (15%). CD19 surface density below detection threshold in remaining cases.",
    "assay_type": "flow",
    "construct_id": "",
    "target_antigen": "CD19",
    "cell_line": "Patient samples",
    "effector_ratio": "",
    "key_metric": "% CD19-neg relapse",
    "metric_value": 28.0,
    "outcome": "failure",
    "notes": "Multi-trial analysis. Antigen loss is primary resistance mechanism."
  },
  {
    "id": "assay-cd19-trogocytosis-025",
    "text_summary": "Trogocytosis-mediated CD19 transfer was identified as a novel resistance mechanism. CD19 CAR-T cells actively strip CD19 from target cell surfaces during immune synapse formation. Flow cytometry showed 40-60% reduction in target cell CD19 MFI after 4h co-culture. Stripped CD19 on CAR-T surfaces triggered fratricide, reducing CAR-T persistence. This mechanism is antigen-independent and affects all CD19-targeted CARs.",
    "assay_type": "flow",
    "construct_id": "",
    "target_antigen": "CD19",
    "cell_line": "Nalm-6 / Raji",
    "effector_ratio": "1:1",
    "key_metric": "% CD19 MFI reduction",
    "metric_value": 50.0,
    "outcome": "partial",
    "notes": "Hamieh et al., Nature 2019. PMID:30814727. Trogocytosis + fratricide."
  },
  {
    "id": "assay-cd28-vs-41bb-exhaust-026",
    "text_summary": "Head-to-head comparison of CD28 vs 4-1BB costimulatory domains in otherwise identical CD19 CARs. After repeated antigen stimulation (3 rounds, 5 days each), CD28-CARs showed 85% PD-1+/TIM-3+ double-positive (exhausted phenotype) vs 42% for 4-1BB CARs. CD28-CARs had higher peak killing but lost >70% of cytolytic activity by round 3. 4-1BB CARs maintained 65% of initial killing. Demonstrates the persistence vs potency tradeoff.",
    "assay_type": "exhaustion",
    "construct_id": "",
    "target_antigen": "CD19",
    "cell_line": "Nalm-6 (serial stim)",
    "effector_ratio": "1:1",
    "key_metric": "% PD-1+/TIM-3+ (CD28)",
    "metric_value": 85.0,
    "outcome": "partial",
    "notes": "Long et al., Nat Med 2015. CD28 = fast but exhaustible; 4-1BB = sustained."
  },
  {
    "id": "assay-bcma-soluble-resist-027",
    "text_summary": "Soluble BCMA (sBCMA) acts as a decoy that inhibits BCMA-targeted CAR-T function. In vitro, physiological sBCMA concentrations (100-500 ng/mL, matching myeloma patient serum levels) reduced BCMA CAR-T killing by 30-45% in 24h cytotoxicity assays. At 500 ng/mL sBCMA, killing of RPMI-8226 dropped from 85% to 52%. Gamma-secretase inhibitors rescued CAR-T function by blocking BCMA shedding.",
    "assay_type": "cytotoxicity",
    "construct_id": "fda-idecabtagene-vicleucel",
    "target_antigen": "BCMA",
    "cell_line": "RPMI-8226 + sBCMA",
    "effector_ratio": "5:1",
    "key_metric": "% killing with sBCMA",
    "metric_value": 52.0,
    "outcome": "partial",
    "notes": "sBCMA decoy mechanism. GSI co-administration rescues function."
  },
  {
    "id": "assay-cd22-cyto-nalm6-028",
    "text_summary": "Anti-CD22 CAR-T cells (m971-based scFv, 4-1BB costimulation) showed moderate cytotoxicity against CD22+ Nalm-6 cells. At 10:1 E:T ratio, 65% killing at 24h — lower than CD19 CARs tested in parallel (92%). Sensitivity to CD22 surface density observed: cells with >5000 molecules/cell showed >80% killing while <1000 molecules/cell showed <30% killing. Supports use in CD19-negative relapse (Fry et al., Nat Med 2018).",
    "assay_type": "cytotoxicity",
    "construct_id": "",
    "target_antigen": "CD22",
    "cell_line": "Nalm-6",
    "effector_ratio": "10:1",
    "key_metric": "% specific lysis",
    "metric_value": 65.0,
    "outcome": "partial",
    "notes": "PMID:29155426. CD22 density-dependent. Rescue after CD19 loss."
  },
  {
    "id": "assay-cd19cd22-dual-029",
    "text_summary": "Bispecific CD19/CD22 dual-targeting CAR-T cells (bicistronic construct) showed synergistic killing in vitro. Against Nalm-6 cells (CD19+/CD22+), 96% killing at 5:1 E:T ratio. Against CD19-knockout cells (CD22+ only), maintained 72% killing. Against CD22-low cells (CD19+ only), maintained 90% killing. Dual targeting prevents single-antigen escape that drives 28% of CD19 CAR-T relapses.",
    "assay_type": "cytotoxicity",
    "construct_id": "",
    "target_antigen": "CD19",
    "cell_line": "Nalm-6 (WT/CD19-KO/CD22-low)",
    "effector_ratio": "5:1",
    "key_metric": "% killing (dual target)",
    "metric_value": 96.0,
    "outcome": "success",
    "notes": "Bicistronic dual CAR. Prevents single-antigen escape."
  },
  {
    "id": "assay-tisa-flow-memory-030",
    "text_summary": "Flow cytometric analysis of tisagenlecleucel products revealed that central memory T-cell (Tcm) frequency in the infusion product predicted clinical response. Products with >40% CD8+ Tcm (CD45RO+/CCR7+/CD62L+) achieved 95% CR rate vs 58% for products with <20% Tcm. The 4-1BB costimulatory domain promoted Tcm differentiation during expansion. This finding informed manufacturing optimization for consistent Tcm enrichment.",
    "assay_type": "flow",
    "construct_id": "fda-tisagenlecleucel",
    "target_antigen": "CD19",
    "cell_line": "Clinical product",
    "effector_ratio": "",
    "key_metric": "% CD8+ Tcm in product",
    "metric_value": 40.0,
    "outcome": "success",
    "notes": "ELIANA correlative. Tcm frequency predicts response. Threshold: 40%."
  },
  {
    "id": "assay-axi-flow-cd4cd8-031",
    "text_summary": "ZUMA-1 product characterization by flow cytometry showed variable CD4:CD8 ratios (range 0.3-8.0, median 1.4). Products with CD4:CD8 ratio between 0.8-2.0 showed highest ORR (87%) vs <60% for extreme ratios. CD8+ T-cells with CCR7-/CD45RA- effector memory phenotype were the dominant functional subset. Baseline patient T-cell fitness (pre-leukapheresis) was the strongest predictor of product quality.",
    "assay_type": "flow",
    "construct_id": "fda-axicabtagene-ciloleucel",
    "target_antigen": "CD19",
    "cell_line": "Clinical product",
    "effector_ratio": "",
    "key_metric": "optimal CD4:CD8 ratio",
    "metric_value": 1.4,
    "outcome": "success",
    "notes": "ZUMA-1 correlative. Product CD4:CD8 ratio affects outcomes."
  },
  {
    "id": "assay-cilta-invivo-mouse-032",
    "text_summary": "In orthotopic MM.1S multiple myeloma mouse model, ciltacabtagene autoleucel achieved complete tumor eradication in 10/10 mice at 1e6 CAR-T cell dose, compared to 6/10 for single-epitope BCMA CAR. BLI showed undetectable tumor signal by day 14 (cilta-cel) vs day 28 (single-epitope). The dual VHH nanobody architecture provides superior avidity that overcomes BCMA density heterogeneity within tumors.",
    "assay_type": "in_vivo",
    "construct_id": "fda-ciltacabtagene-autoleucel",
    "target_antigen": "BCMA",
    "cell_line": "MM.1S orthotopic",
    "effector_ratio": "",
    "key_metric": "complete response rate",
    "metric_value": 100.0,
    "outcome": "success",
    "notes": "Dual VHH vs single-chain head-to-head. Cilta-cel clearly superior."
  },
  {
    "id": "assay-ide-exhaust-033",
    "text_summary": "Analysis of idecabtagene vicleucel products from KarMMa showed that pre-infusion T-cell exhaustion markers predicted clinical outcomes. Products with >50% PD-1+ CAR-T cells had ORR of 55% vs 84% for products with <30% PD-1+. Extended ex vivo culture (>10 days) was associated with increased exhaustion markers. Optimizing manufacturing to minimize culture time while achieving target cell dose is critical.",
    "assay_type": "exhaustion",
    "construct_id": "fda-idecabtagene-vicleucel",
    "target_antigen": "BCMA",
    "cell_line": "Clinical product",
    "effector_ratio": "",
    "key_metric": "% PD-1+ threshold",
    "metric_value": 30.0,
    "outcome": "partial",
    "notes": "KarMMa correlative. Product exhaustion predicts response. <30% PD-1 optimal."
  },
  {
    "id": "assay-tcell-prolif-il15-034",
    "text_summary": "Comparison of cytokine cocktails for CAR-T expansion showed IL-7/IL-15 yielded superior products compared to IL-2 alone. After 10-day expansion, IL-7/IL-15 cultures had 3.2x more Tscm (stem cell memory) cells, 45% less exhaustion markers (PD-1/LAG-3), and 1.8x higher fold expansion. In subsequent cytotoxicity assay, IL-7/IL-15-expanded CAR-T cells maintained 82% killing through 5 rounds of serial stimulation vs 41% for IL-2-expanded.",
    "assay_type": "proliferation",
    "construct_id": "",
    "target_antigen": "CD19",
    "cell_line": "Manufacturing comparison",
    "effector_ratio": "",
    "key_metric": "fold expansion (IL-7/IL-15)",
    "metric_value": 82.0,
    "outcome": "success",
    "notes": "IL-7/IL-15 vs IL-2 manufacturing. Superior Tscm and less exhaustion."
  },
  {
    "id": "assay-eliana-clinical-035",
    "text_summary": "ELIANA trial (tisagenlecleucel in pediatric/young adult B-ALL): Overall remission rate 81% (61/75 patients) with 60% achieving MRD-negative CR by day 28. Median event-free survival 19.1 months. 77% of responders had grade 1-2 CRS, 48% had grade 3-4 CRS. Tocilizumab used in 48% of patients. ICANS in 40% (mostly grade 1-2). Overall survival at 12 months was 76% (Maude et al., NEJM 2018).",
    "assay_type": "in_vivo",
    "construct_id": "fda-tisagenlecleucel",
    "target_antigen": "CD19",
    "cell_line": "",
    "effector_ratio": "",
    "key_metric": "% MRD-neg CR",
    "metric_value": 60.0,
    "outcome": "success",
    "notes": "PMID:29385376. ELIANA pivotal trial. n=75. Pediatric/YA B-ALL."
  },
  {
    "id": "assay-zuma1-clinical-036",
    "text_summary": "ZUMA-1 trial (axicabtagene ciloleucel in DLBCL): ORR 82% with 54% CR in 101 patients with refractory large B-cell lymphoma. Median time to response: 1.0 month. At 27-month follow-up, 39% of patients maintained ongoing response. Grade >=3 CRS in 13%, grade >=3 neurological events in 28%. Peak CAR-T expansion correlated with both response and toxicity (Neelapu et al., NEJM 2017).",
    "assay_type": "in_vivo",
    "construct_id": "fda-axicabtagene-ciloleucel",
    "target_antigen": "CD19",
    "cell_line": "",
    "effector_ratio": "",
    "key_metric": "% CR",
    "metric_value": 54.0,
    "outcome": "success",
    "notes": "PMID:29226797. ZUMA-1 pivotal trial. n=101. Refractory DLBCL."
  },
  {
    "id": "assay-transform-clinical-037",
    "text_summary": "TRANSFORM trial (lisocabtagene maraleucel vs SOC in 2L LBCL): Liso-cel achieved significantly better EFS vs SOC (median 10.1 vs 2.3 months, HR 0.35, p<0.001). CR rate 74% vs 43%. First CAR-T approved in second-line setting. Favorable safety: grade >=3 CRS only 1%, grade >=3 ICANS 4%. Defined CD4:CD8 composition and 4-1BB costimulation contribute to safety profile (Kamdar et al., Lancet 2022).",
    "assay_type": "in_vivo",
    "construct_id": "fda-lisocabtagene-maraleucel",
    "target_antigen": "CD19",
    "cell_line": "",
    "effector_ratio": "",
    "key_metric": "% CR",
    "metric_value": 74.0,
    "outcome": "success",
    "notes": "PMID:36517098. TRANSFORM trial. Liso-cel vs SOC in 2L LBCL."
  },
  {
    "id": "assay-gpc3-cyto-hepg2-038",
    "text_summary": "GPC3-targeted CAR-T cells (humanized GC33 scFv, 4-1BB/CD3z) showed effective killing of GPC3+ HepG2 hepatocellular carcinoma cells. At 5:1 E:T ratio, 73% specific lysis at 24h. Against GPC3-high Hep3B cells, killing increased to 81%. Demonstrates solid tumor targeting feasibility with GPC3, though in vivo efficacy limited by immunosuppressive tumor microenvironment.",
    "assay_type": "cytotoxicity",
    "construct_id": "",
    "target_antigen": "GPC3",
    "cell_line": "HepG2",
    "effector_ratio": "5:1",
    "key_metric": "% specific lysis",
    "metric_value": 73.0,
    "outcome": "success",
    "notes": "HCC solid tumor model. GPC3 targeting. TME remains challenge."
  },
  {
    "id": "assay-her2-cyto-skov3-039",
    "text_summary": "HER2-targeted CAR-T cells with affinity-tuned scFv (4D5-5, reduced affinity for safety) selectively killed HER2-high SKOV3 ovarian cancer cells (78% at 5:1) while sparing HER2-low MCF10A normal breast epithelial cells (<15% killing). This affinity tuning approach addresses the on-target/off-tumor toxicity concern that led to a fatal outcome in an early HER2 CAR-T trial (Morgan et al., 2010).",
    "assay_type": "cytotoxicity",
    "construct_id": "",
    "target_antigen": "HER2",
    "cell_line": "SKOV3",
    "effector_ratio": "5:1",
    "key_metric": "% specific lysis",
    "metric_value": 78.0,
    "outcome": "success",
    "notes": "Affinity-tuned CAR for safety. Spares HER2-low normal tissue."
  },
  {
    "id": "assay-meso-cyto-ovcar3-040",
    "text_summary": "Mesothelin-targeted CAR-T cells (SS1 scFv, 4-1BB costim) killed OVCAR-3 ovarian cancer cells at 68% lysis (10:1 E:T, 24h). Serial stimulation assay showed persistence advantage of 4-1BB costim: maintained 55% killing at round 3. In combination with PD-1 checkpoint blockade, killing increased to 82% and exhaustion markers reduced by 40%. Combination approaches promising for solid tumors.",
    "assay_type": "cytotoxicity",
    "construct_id": "",
    "target_antigen": "Mesothelin",
    "cell_line": "OVCAR-3",
    "effector_ratio": "10:1",
    "key_metric": "% killing + anti-PD-1",
    "metric_value": 82.0,
    "outcome": "success",
    "notes": "Solid tumor CAR-T. PD-1 blockade enhances function in TME."
  },
  {
    "id": "assay-bcma-biallelic-loss-041",
    "text_summary": "Biallelic BCMA loss identified as resistance mechanism in 4/14 (29%) patients relapsing after BCMA CAR-T therapy. Genomic analysis revealed hemizygous BCMA deletion (16p13.13) combined with nonsense or frameshift mutations on the remaining allele. Pre-existing subclonal BCMA-null cells expanded under selective pressure. Complete BCMA loss renders all BCMA-targeted therapies (CAR-T, BiTE, ADC) ineffective.",
    "assay_type": "flow",
    "construct_id": "",
    "target_antigen": "BCMA",
    "cell_line": "Patient samples",
    "effector_ratio": "",
    "key_metric": "% biallelic BCMA loss",
    "metric_value": 29.0,
    "outcome": "failure",
    "notes": "Da Via et al., Nat Med 2021. PMID:33820986. Genomic BCMA loss."
  },
  {
    "id": "assay-cd19-lineage-switch-042",
    "text_summary": "Lineage switch from lymphoid (B-ALL) to myeloid (AML) phenotype observed in 12/115 (10%) pediatric B-ALL patients treated with CD19 CAR-T across multi-institutional analysis. Switch characterized by loss of CD19/CD22/CD10 B-cell markers and gain of CD33/CD117/CD14 myeloid markers. KMT2A rearrangement was present in 9/12 cases (75%), suggesting pre-existing lineage plasticity. AML emerged at median 159 days post-infusion.",
    "assay_type": "flow",
    "construct_id": "",
    "target_antigen": "CD19",
    "cell_line": "Patient samples",
    "effector_ratio": "",
    "key_metric": "% lineage switch",
    "metric_value": 10.0,
    "outcome": "failure",
    "notes": "Multi-center analysis. KMT2A-rearranged ALL at highest risk."
  },
  {
    "id": "assay-armored-il18-043",
    "text_summary": "Armored (4th generation) CAR-T cells engineered to constitutively secrete IL-18 showed enhanced anti-tumor activity in solid tumor models. Against pancreatic Panc02 tumors in immunocompetent mice, IL-18 armored CAR-T achieved 60% complete response vs 10% for standard 2nd-gen CAR-T. IL-18 reprogrammed the immunosuppressive tumor microenvironment by activating endogenous NK cells and M1 macrophages.",
    "assay_type": "in_vivo",
    "construct_id": "",
    "target_antigen": "Mesothelin",
    "cell_line": "Panc02 syngeneic",
    "effector_ratio": "",
    "key_metric": "% CR (armored vs standard)",
    "metric_value": 60.0,
    "outcome": "success",
    "notes": "4th-gen armored CAR. IL-18 reshapes TME. Immunocompetent model."
  },
  {
    "id": "assay-tisa-prolif-expansion-044",
    "text_summary": "Manufacturing characterization of tisagenlecleucel showed median 42-fold expansion during 9-day culture period. Starting from leukapheresis product, T-cells activated with anti-CD3/CD28 beads in presence of IL-2. Transduction with lentiviral vector at MOI 5 achieved median 1.5 VCN (vector copies per diploid genome). Product viability >90% at harvest. Total manufacturing time: 22 days from leukapheresis to release.",
    "assay_type": "proliferation",
    "construct_id": "fda-tisagenlecleucel",
    "target_antigen": "CD19",
    "cell_line": "Manufacturing",
    "effector_ratio": "",
    "key_metric": "fold expansion",
    "metric_value": 42.0,
    "outcome": "success",
    "notes": "Novartis manufacturing. 22-day vein-to-vein. Lentiviral MOI 5."
  },
  {
    "id": "assay-axi-prolif-expansion-045",
    "text_summary": "Axicabtagene ciloleucel manufacturing uses a rapid 6-day expansion protocol with gamma-retroviral vector. Median fold expansion: 25x. Anti-CD3 activation (no beads) with IL-2. Transduction efficiency: median 50% (range 28-74%). Faster manufacturing (6-7 days) than lentiviral products (9-12 days) enables more patients to receive treatment before disease progression. Failed manufacturing rate: 1% (vs ~8% for longer protocols).",
    "assay_type": "proliferation",
    "construct_id": "fda-axicabtagene-ciloleucel",
    "target_antigen": "CD19",
    "cell_line": "Manufacturing",
    "effector_ratio": "",
    "key_metric": "fold expansion",
    "metric_value": 25.0,
    "outcome": "success",
    "notes": "Kite/Gilead. 6-day rapid manufacturing. Gamma-retroviral vector."
  }
]
